MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. The focus of this study will be on the use of cannabinoids in patients suffering from Fibromyalgia or chronic pain, with the primary research sites located in the United States and the United Kingdom. Flora Pharm

READ MORE: http://www.businesswire.com/news/home/20211006005394/en/Flora-Growth-Forms-Flora-Pharma-Division-Launches-Global-Clinical-Trials/?feedref=JjAwJuNHiystnCoBq_hl-W8j9Oi60kFTomUxRDB8jhB8bDel5XZmwWFQYQPHxx__rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3kCXJZE-1b1nXn968wYfofVLkaZDLiczsahzEklD3R10Q==